Pharmacologic management of heart failure and left ventricular systolic dysfunction
Read Online
Share

Pharmacologic management of heart failure and left ventricular systolic dysfunction effect in female, black, and diabetic patients, and cost-effectiveness by

  • 936 Want to read
  • ·
  • 79 Currently reading

Published by U.S. Dept. of Health and Human Services, Public Health Service, Agency for Healthcare Research and Quality in Rockville, Md .
Written in English

Subjects:

  • Heart failure -- Chemotherapy -- Evaluation,
  • Heart failure -- Chemotherapy -- Cost effectiveness,
  • Adrenergic beta blockers -- Therapeutic use -- Evaluation,
  • Angiotensin converting enzyme -- Inhibitors -- Therapeutic use -- Evaluation,
  • Diabetes -- Complications -- Chemotherapy -- Evaluation,
  • Evidence-based medicine,
  • Heart Failure -- drug therapy,
  • Ventricular Dysfunction, Left -- drug therapy,
  • Evidence-Based Medicine -- methods

Book details:

Edition Notes

Statementprepared for Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services ; prepared by Southern California-RAND Evidence-based Practice Center, Santa Monica, CA ; program director, Paul Shekelle, program co-director, Sally Morton ... [et al.].
SeriesEvidence report/technology assessment -- no. 82, AHRQ publication -- no. 03-E045
ContributionsShekelle, Paul G., Morton, Sally C., Southern California Evidence-Based Practice Center/RAND.
Classifications
LC ClassificationsRC685.C53 P437 2003
The Physical Object
Paginationx, 163 p. :
Number of Pages163
ID Numbers
Open LibraryOL17841387M
LC Control Number2003628991
OCLC/WorldCa54960165

Download Pharmacologic management of heart failure and left ventricular systolic dysfunction

PDF EPUB FB2 MOBI RTF

Pharmacologic Management of Heart Failure and Left Ventricular Systolic Dysfunction Effect in Female, Black, and Diabetic Patients, and Cost-Effectiveness Published in: Evidence Report/Technology Assessment: no. 82 (Prepared by the Southern California/RAND Evidence-based Practice Center under contract No. ).Cited by: Pharmacologic management of heart failure and left ventricular systolic dysfunction: effect in female, black, and diabetic patients, and cost-effectiveness. Shekelle P, Morton S, Atkinson S, Suttorp M, Tu W, Heidenreich P, Gubens M, Maglione M, Jungvig L, Roth E, Newberry by: Pharmacologic management of heart failure and left ventricular systolic dysfunction: effect in female, black, and diabetic patients, and cost-effectiveness. Pharmacologic Management of Heart left ventricular systolic dysfunction will be the Heart failure caused by systolic dysfunction affects more than 5 million adults in the United States and Cited by: 3.

Diastolic heart failure occurs when signs and symptoms of heart failure are present but left ventricular systolic function is preserved (i.e., ejection fraction greater than 45 percent).   5 – 8. Aldosterone antagonists are recommended to reduce mortality in patients with heart failure who have current or recent rest dyspnea and in patients with recent myocardial infarction Cited by: 3.   Left ventricular failure occurs when there is dysfunction of the left ventricle causing insufficient delivery of blood to vital body organs. Left ventricular failure can further subdivide into heart failure with preserved ejection fraction (HFpEF with EF over 50%), heart failure with reduced ejection fraction (HFrEF with EF less than 40%), or heart failure with mid-range ejection fraction (EF Author: Johnny Chahine, Heidi Alvey.   failure is to reduce venous pressure and ventricular preload. The reduction of cardiac size, which leads to improved pump efficiency, is of. major importance in systolic failure. In heart failure associated with hypertension, the reduction in blood pressure also reduces afterload.

Click related term for heart failure with reduced ejection fraction: systolic dysfunction, heart failure Initial pharmacologic therapy of heart failure with reduced ejection fraction in adults aspects of management of HFrEF are presented separately including: An overview of management of HFrEF.   Angiotensin-converting enzyme (ACE) inhibitors are indicated in the treatment of all patients with systolic heart failure. A number of landmark randomized, controlled trials 6 – 8 have Cited by: for the Pharmacologic Management of Chronic Heart Failure. in Primary Care Practice. the presence of left ventricular systolic dysfunction, to prevent future development of HF and improve overall recommendations for the pharmacologic management of common diseases treated within the . Patient population: Adult patients with left ventricular systolic dysfunction Objectives: 1) To improve mortality and morbidity for patients with heart failure (HF). 2) To present a framework for treatment of patients with HF. Key Points Ejection fraction (EF) evaluated to determine the etiology as systolic dysfunction rather than.